Skip to main content
SPARC - Logo
Innovations Inspired by life
Menu

Hamburger

  • Our Company
    • Who we are
    • History
    • Culture
    • Board of Directors
    • Leadership Team
  • OUR RESEARCH
    • Therapeutic focus
    • Delivery Technologies
    • Research Programs
    • R&D Pipeline
  • Our Medicines
    • Xelpros®
    • Elepsia® XR
  • Business Development
    • Strategy
    • Partner with us
  • Accreditations And Approvals
    • Good Laboratory Practice
  • Investors
    • Who we are
    • Financials
    • Annual reports
    • Presentations
    • Chairman's Speech
    • Committees of BOD's
    • Shareholding pattern
    • Announcements & Disclosures
    • Policies & Codes
    • Listing Information
    • Board of Directors
    • FAQ’s, Guide Book and Forms for Shareholders
    • Investors Contact
    • Go green
    • IEPF
  • Media
    • Press Releases
    • Presentations
  • Careers
    • Overview
    • Apply Now
  • Contact Us
Our Research » Delivery Technologies
  • Delivery Technologies
    • GRID™
    • Wrap Matrix™
    • Abuse Deterrent Program
    • Nanotecton™ Technology
    • Dry Powder Inhalation
    • TearAct™
    • Lipixelle™
    • Gel Free Reservoir™

LipixelleTM 

LipixelleTM  Technology is a platform for solubilizing ophthalmic drugs with limited water solubility or completely insoluble ophthalmic drugs The currently marketed Latanoprost Eye Drops contain Benzalkonium Chloride (BAK). BAK is a common preservative in topical ocular preparations; however, prolonged use may lead to deleterious effects on the ocular surface, affecting quality of life and reducing adherence to treatment and overall outcomes.

SPARC has developed LipixelleTM Technology platform to formulate Latanoprost in to a novel clear, colorless, BAK-free Ophthalmic Emulsion.

This technology does not require the use of quaternary ammonium preservative/surfactant like Benzalkonium Chloride which may be damaging to the eye.

SMM technology

 

Key Features & Benefits

  • BAK-Free platform for solubilizing ophthalmic drugs with limited water solubility or completely insoluble ophthalmic drugs
  • Uses nonionic surfactant (NIS) to solubilize Latanoprost
  • Contains known ocular lubricant which fortifies the lipid layer in formation of tear film, and uncharged coating is soft to eye surface
  • Reduces risk of ocular surface damage on chronic use
  • Prevents drug from environmental temperature and light fluctuations; stable at room temperature; does not require refrigeration upon storage / transport
Image
device-icon
Technology front

LipixelleTM Technology is a platform for solubilizing ophthalmic drugs with limited water solubility or completely insoluble ophthalmic drugs The currently marketed Latanoprost Eye Drops contain Benzalkonium Chloride (BAK). BAK is a common preservative in topical ocular preparations; however, prolonged use may lead to deleterious effects on the ocular surface, affecting quality of life and reducing adherence to treatment and overall outcomes.

Our Company

  • Who we are
  • history
  • Culture
  • board of directors
  • Leadership team

Our Research

  • Therapeutic focus
  • Delivery Technologies
  • Research Programs
  • R&D Pipeline

Investor Relations

  • Financials
  • Announcements & Disclosures
  • Shareholding pattern
  • Listing Information

Quick Links

Quick Links

  • Business Development
  • Investors
  • Media
  • Careers

Social Connect

  • twitter
  • linkedin

Employee Portal »

Copyright © 2019. Sun Pharma Advanced Research Company Ltd. All rights reserved.
Terms of Use  |   Archival Policy   |   Sitemap
Site Credits